1. Clinical & Scientific Overview
Thiocolchicoside, Tolperisone Hydrochloride & Chlorzoxazone (Spinal & Central Muscle Relaxants) (TIP-MED-000115, Reference Code [7.13]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agents.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.13], p. 85): • Thiocolchicoside (4 mg, 8 mg): Myoril (Sanofi), Nuforce-MR, and in FDCs: Zerodol-MR, Nucoxia-MR, Volini-Maxx. • Tolperisone (150 mg IR, 450 mg SR): Myotop (USV), Tolfree (Cipla), Synaptol. • Chlorzoxazone (250 mg, 500 mg, in FDCs): Mobizox (Sun), Myospaz (Win-Medicare). • Tizanidine (2 mg, 4 mg): Sirdalud (Novartis), Tizan (Sun). • Baclofen (10 mg, 20 mg, 10/20/30 mg XL): Lioresal (Novartis), Riclofen, Spinobak. — Strengths & Dosage Forms: Thiocolchicoside Capsules/Tablets: 4 mg, 8 mg; Tolperisone Tablets: 150 mg, 450 mg SR; Chlorzoxazone FDC Tablets: 250 mg / 500 mg; Tizanidine Scored Tablets: 2 mg, 4 mg; Baclofen Tablets: 5 mg, 10 mg, 20 mg (and 10/20 mg ER)
Thiocolchicoside Capsules/Tablets: 4 mg, 8 mg; Tolperisone Tablets: 150 mg, 450 mg SR; Chlorzoxazone FDC Tablets: 250 mg / 500 mg; Tizanidine Scored Tablets: 2 mg, 4 mg; Baclofen Tablets: 5 mg, 10 mg, 20 mg (and 10/20 mg ER)
3. Mechanism of Action & Pharmacodynamics
Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agents acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agents for Acute painful musculoskeletal spasms (acute low back pain, cervical spondylosis spasm, torticollis—Thiocolchicoside, Tolperisone, Chlorzoxazone, Tizanidine); chronic neurological spasticity due to multiple sclerosis, spinal cord injury, or post-stroke hemiplegia (Baclofen, Tizanidine)..
4. Therapeutic Indications & Evidence-Supported Uses
- Acute painful musculoskeletal spasms (acute low back pain, cervical spondylosis spasm, torticollis—Thiocolchicoside, Tolperisone, Chlorzoxazone, Tizanidine)
- chronic neurological spasticity due to multiple sclerosis, spinal cord injury, or post-stroke hemiplegia (Baclofen, Tizanidine)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: • Thiocolchicoside: 4 mg to 8 mg twice daily (every 12 h) for maximum 5 to 7 consecutive days only! • Tolperisone: 150 mg three times daily after meals (or 450 mg SR OD). • Tizanidine: 2 mg at bedtime or 2–4 mg 2–3 times daily. • Baclofen: Start 5 mg three times daily; titrate gradually to 10–20 mg TDS (reduce in CKD!). Follow physician prescription.
Administration & Meal Timing: Take WITH or immediately AFTER meals! (In particular, Tolperisone oral bioavailability drops by >50–70% if taken on an empty stomach—it MUST be taken with a full meal! Food also reduces GI upset from Thiocolchicoside/Baclofen and keeps Tizanidine absorption consistent). | Twice or three times daily after meals (or bedtime if single dose for nocturnal muscle spasm).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: CRITICAL RENAL ALERT FOR BACLOFEN: Baclofen is excreted 70–80% unchanged by the kidneys! Even a single 5 mg or 10 mg tablet of Baclofen in a patient with eGFR <30 mL/min or on dialysis can trigger acute coma, respiratory depression, and encephalopathy within 24 hours! Avoid Baclofen if eGFR <30 mL/min (and reduce dose if eGFR 30–60 mL/min). Hepatic: Avoid Chlorzoxazone and Tizanidine in hepatic impairment.
Renal: CRITICAL RENAL ALERT FOR BACLOFEN: Baclofen is excreted 70–80% unchanged by the kidneys! Even a single 5 mg or 10 mg tablet of Baclofen in a patient with eGFR <30 mL/min or on dialysis can trigger acute coma, respiratory depression, and encephalopathy within 24 hours! Avoid Baclofen if eGFR <30 mL/min (and reduce dose if eGFR 30–60 mL/min). Hepatic: Avoid Chlorzoxazone and Tizanidine in hepatic impairment.
Renal: CRITICAL RENAL ALERT FOR BACLOFEN: Baclofen is excreted 70–80% unchanged by the kidneys! Even a single 5 mg or 10 mg tablet of Baclofen in a patient with eGFR <30 mL/min or on dialysis can trigger acute coma, respiratory depression, and encephalopathy within 24 hours! Avoid Baclofen if eGFR <30 mL/min (and reduce dose if eGFR 30–60 mL/min). Hepatic: Avoid Chlorzoxazone and Tizanidine in hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Specific Regulatory & Clinical Precautions by Agent: • Thiocolchicoside: Strictly contraindicated in pregnancy, lactation, women of childbearing potential not using contraception (metabolite M2/SL59.0955 causes chromosomal aneuploidy/genotoxicity and teratogenicity!), and epilepsy/seizure history (GABA-A antagonist activity can precipitate seizures!). Maximum duration 7 days orally. • Chlorzoxazone: Risk of idiosyncratic severe hepatotoxicity; avoid in liver disease. • Tizanidine: Causes marked alpha-2 adrenergic hypotension, bradycardia, dry mouth, and hepatotoxicity. • Baclofen: Abrupt withdrawal causes life-threatening rebound spasticity, hyperthermia, rhabdomyolysis, hallucinations, and status epilepticus! Also causes fatal encephalopathy in CKD!
Key Clinical Precautions: Renal: CRITICAL RENAL ALERT FOR BACLOFEN: Baclofen is excreted 70–80% unchanged by the kidneys! Even a single 5 mg or 10 mg tablet of Baclofen in a patient with eGFR <30 mL/min or on dialysis can trigger acute coma, respiratory depression, and encephalopathy within 24 hours! Avoid Baclofen if eGFR <30 mL/min (and reduce dose if eGFR 30–60 mL/min). Hepatic: Avoid Chlorzoxazone and Tizanidine in hepatic impairment.
8. Adverse Effects Profile
- Drowsiness, sedation, dizziness, asthenia/muscular weakness (Note: Tolperisone and Thiocolchicoside cause significantly less sedation than Tizanidine, Chlorzoxazone, or Baclofen), diarrhoea (Thiocolchicoside), dry mouth and postural hypotension (Tizanidine).
- Baclofen Neurotoxicity/Coma in Renal Failure, Seizures (Thiocolchicoside in predisposed patients, or Baclofen withdrawal), Severe Hypotension/Bradycardia (Tizanidine + Ciprofloxacin), Idiosyncratic Acute Liver Injury (Chlorzoxazone, Tizanidine), Anaphylaxis (rare with Tolperisone).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CONTRAINDICATED INTERACTION: Tizanidine + Ciprofloxacin (or Fluvoxamine)! Ciprofloxacin is a potent CYP1A2 inhibitor that increases Tizanidine plasma concentrations 10- to 33-fold, causing profound, life-threatening hypotension, bradycardia, and coma! Additive CNS depression with opioids, benzodiazepines, pregabalin, antihistamines, and alcohol
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. If dispensing Tizan (Tizanidine), verify the patient is NOT taking Ciprofloxacin. 2. If dispensing Tolperisone (Myotop/Tolfree), instruct the patient to take it immediately after eating a meal (it barely absorbs on an empty stomach). 3. If dispensing Thiocolchicoside (Zerodol-MR / Nucoxia-MR), confirm duration is ≤7 days and patient is not pregnant or epileptic. 4. If dispensing Baclofen, check kidney function (creatinine/eGFR) first!
- Meal & Clock Timing Instruction: Take WITH or immediately AFTER meals! (In particular, Tolperisone oral bioavailability drops by >50–70% if taken on an empty stomach—it MUST be taken with a full meal! Food also reduces GI upset from Thiocolchicoside/Baclofen and keeps Tizanidine absorption consistent). (Twice or three times daily after meals (or bedtime if single dose for nocturnal muscle spasm).)
- Missed Dose Protocol: For acute spasm: skip if close to next dose. For chronic Baclofen: take as soon as remembered (never allow supply to run out abruptly).
- Geriatric Dispensing Pearl: Skeletal muscle relaxants are listed in Beers Criteria as potentially inappropriate in the elderly due to sedation, weakness, and fractures. If a non-sedating option is required for short-term spasm in an elderly patient, Tolperisone (taken with meals) causes minimal CNS sedation compared to Chlorzoxazone or Tizanidine.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Thiocolchicoside Capsules/Tablets: 4 mg, 8 mg; Tolperisone Tablets: 150 mg, 450 mg SR; Chlorzoxazone FDC Tablets: 250 mg / 500 mg; Tizanidine Scored Tablets: 2 mg, 4 mg; Baclofen Tablets: 5 mg, 10 mg, 20 mg (and 10/20 mg ER)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.13] (p. 85)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.15] Ketorolac Tromethamine — Potent Pyrrolizine Carboxylic Acid Non-Selective COX Inhibitor An
- [7.16] Mefenamic Acid — Anthranilic Acid (Fenamate) COX-1 / COX-2 Inhibitor & Prostagland
- [7.17] Celecoxib — Selective Cyclooxygenase-2 (COX-2) Inhibitor — Diaryl-Substituted
- [7.18] Indomethacin — Potent Indole Acetic Acid Non-Selective COX Inhibitor (Schedule H
